Abstract
In D2O (pD 6.8), increasing concentrations of norepinephrine were accompanied by an upfield shift of the phenyl proton signal. At all concentrations the addition of 1 mole of ATP for 4 moles of the amine caused the signal to move further upfield. To delineate stacking from other electronic processes in solutions of norepinephrine, dimethyl sulfoxide (DMSO), a pure hydrogen bond acceptor, was utilized. In this solvent, increasing concentrations of norepinephrine were accompanied by a downfield shift of the phenyl proton signal, whereas phenylethylamine, a compound incapable of hydrogen bonding, showed no change. The downfield shift observed with norepinephrine was explained by increased hydrogen bonding between catechol OH groups in the more concentrated solutions. If hydrogen bonding were the only factor influencing the magnetic field, the replacement of DMSO by D2O, a hydrogen bond donator and acceptor, should cause a continuous downfield shift of the phenyl proton signal. In 0.5 M norepinephrine the signal moved downfield until the D2O reached 80 volumes/100 volumes but then reversed its course. The upfield shift was attributed to stacking of the aromatic rings. In all mixtures of DMSO and D2O, the phenyl proton signal of norepinephrine was moved upfield by the addition of adenosine. These shifts were explained by the formation of complexes between the adenine and catechol rings. In D2O, ATP produced a greater upfield shift than did adenosine. This observation indicated augmented ring stacking in the catecholamine· ATP complexes. In D2O, increasing the temperature of the norepinephrine·ATP complex from 28° to 80° caused a downfield shift of the phenyl—H and adenine 2H signals, whereas the adenine 8H showed no change. The phenyl—H signal of norepinephrine alone was not affected by temperature. These observations are in harmony with a Dreiding model of the 4:1 norepinephrine·ATP complex in which the adenine 2H is located between two catechol rings.
- Copyright © 1981 by The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|